| Name | Title | Contact Details |
|---|
Three Rivers Pharmaceuticals is a Warrendale, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases.
Elicio is committed to transforming the lives of patients and their families by re-engineering the body`s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body`s own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. Elicio`s lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio`s Amphiphile vaccines target and concentrate in the lymph nodes resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.
FluidForm Bio™ is creating living human tissue for better treatment of disease. Our patented FRESH™ technology is a revolutionary platform designed to build tissue using cells, proteins, and nothing else. Through partnerships with top life science companies, our technology has been validated to produce the highest quality tissue in a variety of applications. We deliver human tissue that is indistinguishable from the real thing by integrating breakthrough innovations in 3D printing, computational and synthetic biology, AI, and advanced materials science. Our living tissue will offer therapies to countless patients who deserve better treatment options.
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including: Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client`s needs.